You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康辰藥業(603590.SH):擬收購泰凌國際100%股份 從而實現對密蓋息資產的收購
格隆匯 04-21 21:47

格隆匯4月21日丨康辰藥業(603590.SH)公佈,2020年4月21日,公司、子公司與相關主體簽署《關於支付現金購買資產協議》。公司子公司康辰生物向泰凌國際股東BVI公司支付現金9億元(暫定對價,分三期支付)購買其持有的泰凌國際100%股份,從而實現對密蓋息資產的收購;收購完成後,泰凌醫藥子公司泰凌亞洲對康辰生物進行增資,預計增資金額3.6億元,增資完成後,該公司將持有康辰生物40%股權。

次收購密蓋息資產,業績承諾方承諾密蓋息相關業務2021-2023年的淨利潤分別不低於0.8億元、1億元和1.2億元。但如行業環境或政策發生重大不利變化,或此次收購後由於企業文化、管理模式、客户資源差異公司未能對標的資產進行有效整合,則此次收購可能存在不能達到預期目標的風險。

標的公司擁有的產品包括密蓋息注射劑、密蓋息鼻噴劑,本次收購完成前標的公司授權泰凌醫藥下屬公司泰凌香港等從事密蓋息的採購、銷售、推廣等業務。

標的公司的密蓋息產品主要銷售分佈在中國境內、越南、中國台灣、泰國等國家和地區,其中以中國大陸銷售為主。

交易主要為收購密蓋息資產項目。公司將通過收購密蓋息資產及取得特立帕肽商業化權利,進軍骨科藥品市場,符合“通過外延型收購及投資加快業務增長”、“進一步增強研發能力,豐富產品組合”的發展計劃,有助於豐富公司的產品結構,優化業務佈局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account